Abstract
Previous studies by us have strongly indicated a role for theN-methyl-d-aspartate (NMDA) receptor in the pathogenesis of experimental allergic encephalomyelitis (EAE) and, moreover, the loss of blood-brain barrier (BBB) integrity implicit in the disease. The current investigation has used the NMDA receptor antagonist memantine to modify the neurological course of EAE and, in particular, prevent BBB breakdown. Memantine was administered orally either semiprophylactically, from day 7 postinoculation (PI), or therapeutically, 10 to 11 days PI. Semiprophylactic administration of drug at 60 mg/kg b.wt. significantly restored BBB integrity, reduced symptoms, and limited inflammatory lesions (p < 0.05), when assessed 12 days PI. Higher concentrations of memantine did not notably advance disease improvements observed at 60 mg/kg b.wt., and 40-mg/kg b.wt. doses only reduced histological scores (p < 0.05). Therapeutic application of memantine was found to be as effective as semiprophylactic dosing. Administration of drug at 60 mg/kg b.wt. was demonstrated as the optimum dose, significantly reducing disease, BBB permeability, and lesions (p < 0.01). Extended studies revealed that, after cessation of memantine treatment using either dosing regime, any subsequent appearance of disease was suppressed in severity and duration. We have provided further strong evidence in support of a role for the NMDA receptor in the development of EAE and, in particular, the loss of BBB function and recruitment of inflammatory cells. Moreover, memantine is therapeutically efficacious, suggesting the NMDA receptor as a viable pharmacological target for future treatment of human neurological conditions such as multiple sclerosis.
Footnotes
-
↵1 Current address: Solupharm Limited, UK, Biomedical Sciences Division, Faculty of Health and Social Science, University of Luton, Park Square, Luton LU1 3JU, UK.
-
↵2 Current address: Solupharm Limited, UK, William Harvey Research Limited, St. Bartholomew's Hospital Medical College, Charterhouse Square, London EC1M 6BQ, UK.
-
This study was supported by SEARCH, a registered UK charity.
- Abbreviations:
- BBB
- blood-brain barrier
- MS
- multiple sclerosis
- EAE
- experimental allergic encephalomyelitis
- CNS
- central nervous system
- NMDA
- N-methyl-d-aspartate
- PBS
- phosphate-buffered saline
- PI
- postinoculation
- EVBE
- extravascular blood equivalent
- MK-801
- dizocilpine maleate
- Received October 4, 2001.
- Accepted March 4, 2002.
- The American Society for Pharmacology and Experimental Therapeutics
JPET articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|